<<But then again, it was exactly for such an unforeseeable event as the FDA's clinical hold that an in-licensing was first considered>>
That's actually not correct. While the insurance angle was part of it, the initial impetus came from a breadth of pipeline issue--and the possibility of a long delay between a CX717/701 ouitlicensing and the availability of CX1501 for an orphan indication.
Market Data 
Markets 
AI
